Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2015 1
2016 1
2017 3
2018 4
2019 9
2020 6
2021 8
2022 11
2023 10
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.
Choueiri TK, Eto M, Motzer R, De Giorgi U, Buchler T, Basappa NS, Méndez-Vidal MJ, Tjulandin S, Hoon Park S, Melichar B, Hutson T, Alemany C, McGregor B, Powles T, Grünwald V, Alekseev B, Rha SY, Kopyltsov E, Kapoor A, Alonso Gordoa T, Goh JC, Staehler M, Merchan JR, Xie R, Perini RF, Mody K, McKenzie J, Porta CG. Choueiri TK, et al. Among authors: basappa ns. Lancet Oncol. 2023 Mar;24(3):228-238. doi: 10.1016/S1470-2045(23)00049-9. Lancet Oncol. 2023. PMID: 36858721 Clinical Trial.
Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial.
Yang JC, Han B, De La Mora Jiménez E, Lee JS, Koralewski P, Karadurmus N, Sugawara S, Livi L, Basappa NS, Quantin X, Dudnik J, Ortiz DM, Mekhail T, Okpara CE, Dutcus C, Zimmer Z, Samkari A, Bhagwati N, Csőszi T. Yang JC, et al. Among authors: basappa ns. J Thorac Oncol. 2024 Jun;19(6):941-953. doi: 10.1016/j.jtho.2023.12.023. Epub 2023 Dec 29. J Thorac Oncol. 2024. PMID: 38159809 Free article. Clinical Trial.
Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study.
Motzer RJ, Choueiri TK, Hutson T, Young Rha S, Puente J, Lalani AA, Winquist E, Eto M, Basappa NS, Tannir NM, Vaishampayan U, Bjarnason GA, Oudard S, Grünwald V, Burgents J, Xie R, McKenzie J, Powles T. Motzer RJ, et al. Among authors: basappa ns. Eur Urol. 2024 Jul;86(1):4-9. doi: 10.1016/j.eururo.2024.03.015. Epub 2024 Apr 6. Eur Urol. 2024. PMID: 38582713 Free article. Clinical Trial.
Management algorithms for metastatic prostate cancer.
Malone S, Shayegan B, Basappa NS, Chi K, Conter HJ, Hamilton RJ, Hotte SJ, Saad F, So AI, Park-Wyllie L, Hew H, McLeod D, Gotto G. Malone S, et al. Among authors: basappa ns. Can Urol Assoc J. 2020 Feb;14(2):50-60. doi: 10.5489/cuaj.5840. Can Urol Assoc J. 2020. PMID: 31039111 Free PMC article. Review.
Setting Research Priorities for Kidney Cancer.
Jones JM, Bhatt J, Avery J, Laupacis A, Cowan K, Basappa NS, Basiuk J, Canil C, Al-Asaaed S, Heng DYC, Wood L, Stacey D, Kollmannsberger C, Jewett MAS. Jones JM, et al. Among authors: basappa ns. Eur Urol. 2017 Dec;72(6):861-864. doi: 10.1016/j.eururo.2017.04.011. Epub 2017 May 8. Eur Urol. 2017. PMID: 28495043
Perioperative chemotherapy for muscle invasive bladder cancer.
Rudzinski JK, Basappa NS, North S. Rudzinski JK, et al. Among authors: basappa ns. Curr Opin Support Palliat Care. 2015 Sep;9(3):249-54. doi: 10.1097/SPC.0000000000000148. Curr Opin Support Palliat Care. 2015. PMID: 26125306 Review.
Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Takemura K, Lemelin A, Ernst MS, Wells JC, Saliby RM, El Zarif T, Labaki C, Basappa NS, Szabados B, Powles T, Davis ID, Wood LA, Lalani AA, McKay RR, Lee JL, Meza L, Pal SK, Donskov F, Yuasa T, Beuselinck B, Gebrael G, Agarwal N, Choueiri TK, Heng DYC. Takemura K, et al. Among authors: basappa ns. Eur Urol. 2024 Jan 29:S0302-2838(24)00005-8. doi: 10.1016/j.eururo.2024.01.006. Online ahead of print. Eur Urol. 2024. PMID: 38290965 Free article.
Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Takemura K, Ernst MS, Navani V, Wells JC, Bakouny Z, Donskov F, Basappa NS, Wood LA, Meza L, Pal SK, Szabados B, Powles T, Beuselinck B, McKay RR, Lee JL, Ernst DS, Kapoor A, Yuasa T, Choueiri TK, Heng DYC. Takemura K, et al. Among authors: basappa ns. Eur Urol Oncol. 2024 Jun;7(3):501-508. doi: 10.1016/j.euo.2023.10.002. Epub 2023 Oct 31. Eur Urol Oncol. 2024. PMID: 37914579
2022 American Society of Clinical Oncology (ASCO): Meeting highlights.
Black PC, Fallah-Rad N, Loblaw A, Kassouf E, Keyes M, Basappa NS, Swaminath A. Black PC, et al. Among authors: basappa ns. Can Urol Assoc J. 2022 Sep;16(9):E499-E504. doi: 10.5489/cuaj.8097. Can Urol Assoc J. 2022. PMID: 36122414 Free PMC article. No abstract available.
57 results